Core Viewpoint - Cognition Therapeutics, Inc. (CGTX) has experienced a bearish price trend recently, losing 9.6% over the past week, but the formation of a hammer chart pattern suggests a potential trend reversal as buying interest may be increasing [1][2]. Technical Analysis - The hammer chart pattern indicates a potential bottom in the stock price, suggesting that selling pressure may be exhausting and that bulls could be gaining control [2][4]. - A hammer pattern forms when there is a small candle body with a long lower wick, typically occurring during a downtrend, signaling a possible reversal if it appears at the bottom of the trend [3][4]. Fundamental Analysis - There has been a positive trend in earnings estimate revisions for CGTX, which is a bullish indicator that could lead to price appreciation in the near term [6]. - The consensus EPS estimate for CGTX has increased by 14.1% over the last 30 days, indicating that analysts expect better earnings than previously predicted [7]. - CGTX holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks, which typically outperform the market [8].

– Topline results in second dementia indication expected to be reported in December 2024 – PURCHASE, N.Y., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that the last patient has completed their final clinic visit in the Phase 2 SHIMMER study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB). The Company anticipates that topline results will be available in ...

Core Insights - Cognition Therapeutics, Inc. reported a 95% reduction in cognitive decline in patients treated with CT1812 who had lower plasma p-tau217 levels, indicating the drug's potential to modify the disease progression of Alzheimer's [1][2][3] Group 1: Study Findings - The Phase 2 'SHINE' study involved 153 adults with mild-to-moderate Alzheimer's disease, focusing on safety, tolerability, and cognitive function [4] - Participants with lower plasma p-tau217 levels experienced a 2.7-point improvement on the ADAS-Cog11 scale compared to placebo over six months [2][4] - Key biomarkers reflecting Alzheimer's disease pathology showed normalization in CT1812-treated participants, including reductions in GFAP, NfL, Aβ42, and Aβ40 [3][4] Group 2: Future Plans - The company plans to present comprehensive biomarker results at scientific conferences in 2025 and intends to meet with the FDA to discuss the findings and Phase 3 program design [3][4] - Ongoing recruitment for the START study and completed enrollment in the SHIMMER study indicate the company's commitment to advancing CT1812's clinical development [9][10] Group 3: About CT1812 - CT1812 is an experimental small molecule that targets the sigma-2 receptor complex, aiming to displace toxic Aβ oligomers and regulate cellular processes affected by Alzheimer's disease [8] - The median baseline level of plasma p-tau217 in the SHINE study was found to be 1.0 pg/mL, with participants categorized based on levels above or below this median [6][7]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40886 Cognition Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 13-436 ...

Exhibit 99.1 Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update - CT1812 slowed cognitive decline by 95% in Alzheimer's disease patients with lower levels of plasma p-tau217 in a pre-specified analysis from Phase 2 SHINE study presented at CTAD - - On track to report topline results from Phase 2 SHIMMER study investigating CT1812 in patients with mild-to-moderate dementia with Lewy bodies (DLB) by end of 2024 - Purchase, NY – November 13, 20 ...

Clinical Trial Progress - CT1812 demonstrated a 95% slowing of cognitive decline on the ADAS-Cog11 scale and a 108% slowing on the MMSE scale in Alzheimer's disease patients with baseline p-tau217 levels below the median in the Phase 2 SHINE study [1][3] - The Phase 2 SHIMMER study investigating CT1812 in mild-to-moderate dementia with Lewy bodies (DLB) is on track to report topline results by the end of 2024 [1][2] - Enrollment continues in the Phase 2 START study for early Alzheimer's disease and the Phase 2 MAGNIFY study for geographic atrophy secondary to dry age-related macular degeneration [3] Financial Performance - Cash and cash equivalents as of September 30, 2024, were approximately $22.0 million, with $53.6 million in remaining grant funds from the NIA, sufficient to fund operations into Q2 2025 [4] - Research and development expenses decreased to $11.4 million in Q3 2024 from $11.7 million in Q3 2023, primarily due to lower costs with contract manufacturing organizations [5] - General and administrative expenses remained stable at $3.1 million in Q3 2024 compared to the same period in 2023 [6] - The company reported a net loss of $9.9 million, or $(0.25) per share, in Q3 2024, compared to a net loss of $6.7 million, or $(0.22) per share, in Q3 2023 [7] Strategic and Corporate Updates - The company plans to request an end-of-Phase 2 meeting with the FDA to review CT1812's safety, tolerability, and results from the SHINE study, aiming to align on a pivotal Phase 3 program design [2] - DLB, the second most common neurodegenerative disease, lacks disease-modifying treatments, and the SHIMMER study aims to provide safety and tolerability data for this under-studied population [2] - The company presented baseline characteristics of participants in the Phase 2 SHIMMER study at the CTAD conference, confirming enrollment of individuals with mild-to-moderate DLB [3]

- Patient characteristics are consistent with other DLB studies - PURCHASE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, presented participant baseline characteristics in the Phase 2 ‘SHIMMER’ study of mild-to-moderate dementia with Lewy bodies (DLB). The poster is being presented at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference ...

- Results show CT1812 dramatically slowed cognitive decline in patients with lower levels of plasma p-tau217, an important biomarker of Alzheimer's disease pathology - - ADAS-Cog 11 scores showed 95% slowing of decline - - MMSE scores showed 108% slowing of decline - - Pre-specified analysis from SHINE study presented by Dr. Michael Woodward at CTAD 2024 - - Company hosting investor webinar on October 30, 2024 to review findings - PURCHASE, N.Y., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc ...

Presenting prespecified analysis of cognitive impact on plasma p-Tau 217 subgroups in ‘SHINE’ Poster Presentation details baseline characteristics from the signal-finding ‘SHIMMER’ trial in DLB PURCHASE, N.Y., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, announced Michael Woodward, MD, FRACP, head of dementia research at Austin Health in Melbourne, Australia, will ...

PURCHASE, N.Y., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the "Company" or "Cognition") (NASDAQ: CGTX), a clinical-stage company developing drugs to treat neurodegenerative disorders, today announced the Company's president and CEO Lisa Ricciardi will participate in a panel discussion titled Frontiers in Neuroscience during the 3rd Annual Roth Healthcare Opportunities Conference on October 9, 2024. Ms. Ricciardi also will host one-on-one investor meetings during which she will highligh ...